Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 13/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | AHR | P35869 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | PTGFR | P43088 | 1/20 | 0.41 |
| ▸ | LTB4R | Q15722 | 2/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1931392 | 0.93 | HTT (0.43) | RORCMAPTMAPK1AHRSMN1; SMN2 | |
| SCHEMBL1932714 | 0.85 | RORC (0.43) | RORCPPARG | |
| SCHEMBL1932541 | 0.83 | RORC (0.50) | RORCMAPTPPARG | |
| SCHEMBL1931672 | 0.79 | HPGD (0.37) | RORCMAPTHTT | |
| SCHEMBL4497581 | 0.78 | ABCC9 (0.41) | RORCMAPK1PTGFRRAB9A | |
| SCHEMBL1931204 | 0.77 | RORC (0.43) | RORCMAPTPPARGRAB9A | |
| SCHEMBL4509705 | 0.73 | PDE4D (0.38) | RORCMAPTSMN1; SMN2HTTRAB9A | |
| SCHEMBL1932592 | 0.73 | MAPT (0.45) | RORCMAPTSMN1; SMN2PPARGRAB9A | |
| SCHEMBL321846 | 0.73 | MAPT (0.38) | RORCMAPT | |
| SCHEMBL1933051 | 0.73 | RORC (0.43) | RORCMAPTPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8633216-B2 | Imidazo[1,5-a]pyridine derivatives, method for preparing same and pharmaceutical compositions containing same | SANOFI (FR) | 2014-01-21 | — | — | US | disclosed |
| US-8008321-B2 | Imidazo[1,5-a]pyridin-3-yl)(3-methoxy-4-nitrophenyl)methanone; a and b fibroblast growth factor receptors (FGFR) antagonist; anticarcinogenic, antitumor: lung, breast, prostate, melanomas, gliomas; antiinflammatory, vascular smooth muscle cells: atherosclerosis, restenosis, stent and bypass complications | SANOFI-AVENTIS (FR) | 2011-08-30 | — | — | US | disclosed |
| US-20110136856-A1 | Novel imidazo[1,5-a]pyridine derivatives, method for preparing same and pharmaceutical compositions containing same | SANOFI-AVENTIS (FR) | 2011-06-09 | — | — | US | disclosed |
| US-20080108648-A1 | Novel imidazo[1,5-a] pyridine derivatives, method for preparing same and pharmaceutical compositions containing same | SANOFI-AVENTIS (FR) | 2008-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108648-A1 | Novel imidazo[1,5-a] pyridine derivatives, method for preparing same and pharmaceutical compositions containing same | CYP3A5, CYP4B1, CYP3A7 | RORC 279/4885MAPT 2878/4885MAPK1 926/4885 |
| US-20110136856-A1 | Novel imidazo[1,5-a]pyridine derivatives, method for preparing same and pharmaceutical compositions containing same | P2RX6, IL5, ATIC | RORC 464/4885MAPT 2116/4885MAPK1 648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.